BIIB vs IMUX
BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA. IMUX: Immunic is a late-stage biotechnology firm developing oral, small-molecule treatments for multiple sclerosis and other neurodegenerative diseases, led by its flagship candidate, vidofludimus calcium.
Side-by-side fundamentals
| Metric | BIIB | IMUX | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $243.10 | $7.41 | |
| Market cap | $35.9B | $101M | |
| P/E as of 2026-10-20 | 26.14 | n/a | |
| Net margin FY2025, SEC XBRL | +13.1% | n/a | |
| Operating margin FY2021, SEC XBRL | +25.9% | n/a | |
| ROE FY2025, SEC XBRL | +7.1% | n/a | |
| ROA FY2025, SEC XBRL | +4.4% | -404.0% | BIIB higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-03-31 | 0.34 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +2.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.50 | 1.07 | |
| 1-year return as of 2026-10-20 close | +65.8% | -11.4% | BIIB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.